Covalon Study Shows VALGuard Reduces Hospital Infection Rates

What's Happening?

Covalon Technologies Ltd. has published a clinical study demonstrating the effectiveness of its VALGuard® Vascular Access Line Guard in reducing central line-associated bloodstream infections (CLABSIs) at the Children's Hospital at Montefiore. The study, published in the Journal of the Association for Vascular Access, reports a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024. The VALGuard® device, a transparent barrier for IV line connections, significantly decreased infection rates in both the Pediatric Critical Care Unit and Acute Care Units, showcasing its potential as a vital tool in infection prevention protocols.

Why It's Important?

CLABSIs are a major concern in healthcare, leading to increased mortality rates and substantial costs. The study's findings highlight the importance of innovative medical technologies in preventing these infections, potentially saving lives and reducing healthcare expenses. The success of VALGuard® could encourage wider adoption of similar devices, improving patient safety and outcomes across the U.S. healthcare system. This advancement aligns with ongoing efforts to enhance infection control measures in hospitals, addressing a critical public health issue.

What's Next?

Following the study's publication, Covalon plans to showcase the findings at upcoming medical conferences, including the ANCC National Magnet Conference. The company aims to expand the use of VALGuard® in more healthcare facilities, leveraging the study's results to support its growth strategy in the Vascular Access and Surgical Consumables segment. Healthcare providers may consider integrating VALGuard® into their infection prevention protocols, potentially leading to broader industry changes in how CLABSIs are managed.